Abstract:BACKGROUND: Exacerbations associated with chronic lung infection with Pseudomonas aeruginosa are a major contributor to morbidity, mortality and premature death in cystic fibrosis. Such exacerbations are treated with antibiotics, which generally lead to an improvement in lung function and reduced sputum P. aeruginosa density. This potentially suggests a role for the latter in the pathogenesis of exacerbations. However, other data suggesting that changes in P. aeruginosa sputum culture status may not reliably predict an improvement in clinical status, and data indicating no significant changes in either total bacterial counts or in P. aeruginosa numbers in sputum samples collected prior to pulmonary exacerbation sheds doubt on this assumption. We used our recently developed lung segmental model of chronic Pseudomonas infection in sheep to investigate the lung microbiota changes associated with chronic P. aeruginosa lung infection and the impact of systemic therapy with colistimethate sodium (CMS).METHODOLOGY/PRINCIPAL FINDINGS: We collected protected specimen brush (PSB) samples from sheep (n = 8) both prior to and 14 days after establishment of chronic local lung infection with P aeruginosa. Samples were taken from both directly infected lung segments (direct) and segments spatially remote to such sites (remote). Four sheep were treated with daily intravenous injections of CMS between days 7 and 14, and four were treated with a placebo. Necropsy examination at d14 confirmed the presence of chronic local lung infection and lung pathology in every direct lung segment. The predominant orders in lung microbiota communities before infection were Bacillales, Actinomycetales and Clostridiales. While lung microbiota samples were more likely to share similarities with other samples derived from the same lung, considerable within- and between-animal heterogeneity could be appreciated. Pseudomonadales joined the aforementioned list of predominant orders in lung microbiota communities after infection. Whilst treatment with CMS appeared to have little impact on microbial community composition after infection, or the change undergone by communities in reaching that state, when Gram negative organisms (excluding Pseudomonadales) were considered together as a group there was a significant decrease in their relative proportion that was only observed in the sheep treated with CMS. With only one exception the reduction was seen in both direct and remote lung segments. This reduction, coupled with generally increasing or stable levels of Pseudomonadales, meant that the proportion of the latter relative to total Gram negative bacteria increased in all bar one direct and one remote lung segment.CONCLUSIONS/SIGNIFICANCE: The proportional increase in Pseudomonadales relative to other Gram negative bacteria in the lungs of sheep treated with systemic CMS highlights the potential for such therapies to inadvertently select or create a niche for bacteria seeding from a persistent source of chronic infection.

Pathogenic Effects of Biofilm with Chronic Pseudomonas Aeruginosa Lung Infection in Rats

Ciprofloxacin Plus Erythromycin or Ambroxol Ameliorates Endotracheal Tube-Associated Pseudomonas Aeruginosa Biofilms in A Rat Model

Pseudomonas Aeruginosa Alginate is Refractory to Th1 Immune Response and Impedes Host Immune Clearance in a Mouse Model of Acute Lung Infection.

Effects of lasR rhlR defects on chronic Pseudomonas aeruginosa lung infection in rats

Expression of TNF-α in a Rat Model of Chronic Pseudomonas Aeruginosa Biomembrane Associated with Lung Infection

Promoted Neutrophil Respiratory Burst Makes Elimination Of Mucoid Pseudomonas Aeruginosa Biofilms More Difficult By Enhancing Alginate Production

Effect of Ambroxol on Pneumonia Caused by Pseudomonas Aeruginosa with Biofilm Formation in an Endotracheal Intubation Rat Model

Combined Effects of Clarithromycin and Gatifloxacin on Experimental Pne Umonia with Pseudomonas Aeruginosa in Rats As a Model for Biofilm-Associated in Fection

Poly (acetyl, arginyl) glucosamine disrupts Pseudomonas aeruginosa biofilms and enhances bacterial clearance in a rat lung infection model

Synergistic Effects of Aminoglycosides and Fosfomycin on Pseudomonas Aeruginosa in Vitro and Biofilm Infections in a Rat Model

Airway Acidification Impaired Host Defense Against Pseudomonas Aeruginosa Infection by Promoting Type 1 Interferon Β Response

Synergistic Activity of Berberine with Azithromycin Against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung in Vitro and in Vivo.

Effects of antibiotic treatment and phagocyte infiltration on development of <i>Pseudomonas aeruginosa</i> biofilm-Insights from the application of a novel PF hydrogel model <i>in vitro</i> and <i>in vivo</i>

A Model of Intracellular Persistence of Pseudomonas aeruginosa in Airway Epithelial Cells

The evidence of evasion of host defense of Pseudomonas aeruginosa biofilm-associated with chronic pulmonary infection in rats

Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c mice in a novel chronic wound model

Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment

In Vivo Pharmacokinetics/Pharmacodynamics of Colistin and Imipenem in Pseudomonas Aeruginosa Biofilm Infection

Effect of L-arginine on cystic fibrosis Pseudomonas aeruginosa biofilms

In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection

Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium